A r t i c l e s
Parkinson's disease is a neurodegenerative disorder affecting approximately 1% of the population over the age of 60 years, with a lifetime incidence of over 2%. Parkinson's disease is characterized clinically by resting tremor, bradykinesia, rigidity, postural instability, and a variety of other motor and non-motor symptoms and pathologically by the loss of dopamine-producing neurons in the substantia nigra pars compacta in association with the presence of Lewy bodies in some surviving neurons 1 . Most Parkinson's disease cases are sporadic with unknown etiology. Rare cases of familial Parkinson's disease have provided unique resources for the identification of Parkinson's disease-linked genetic defects and for the development of cellular and animal models for a better understanding of pathogenesis 2, 3 . Since the identification of SNCA (encoding α-synuclein) as the first Parkinson's disease-linked gene 4 , several other causative or risk-associated genes have been discovered for Parkinson's disease or other parkinsonian disorders [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Among the disease-causing genes, mutations in SNCA and LRRK2 or an increase in SNCA copy number is linked to Lewy body-confirmed Parkinson's disease. This topic has been comprehensively reviewed by Langston et al. 1, 23 . However, despite extensive ongoing studies of previously identified molecular targets, the pathogenic mechanisms underpinning Parkinson's disease remain largely elusive 24 .
Here we show that mutations in TMEM230 lead to clinically typical, Lewy body-confirmed Parkinson's disease. Our findings suggest that defects in synaptic vesicle trafficking underlie Parkinson's disease pathogenesis, with implications for the development of therapeutics.
RESULTS

A locus for dominant Lewy body-confirmed Parkinson's disease on 20p
We have followed and studied a large North American family of northern European ancestry with Parkinson's disease (family 9853) for over two decades. This family included 81 members, of whom 15 were affected (Supplementary Fig. 1 ). Detailed clinical information was obtained for 14 affected individuals who exhibited variable symptoms Identification of TMEM230 mutations in familial Parkinson's disease A r t i c l e s of typical Parkinson's disease, including bradykinesia, resting tremor, rigidity and postural instability. The symptoms responded well to levodopa therapy in most cases. The mean age at disease onset was 67.0 ± 9.5 (s.d.) years (range of 48-85 years). Death occurred an average of 13.2 ± 4.1 (s.d.) years after disease onset. Pathological analysis of autopsy samples from three affected individuals (II-4, II6 and II-14) found Parkinson's disease pathology, including marked loss of dopaminergic neurons and the presence of typical Lewy bodies and Lewy neurites in the substantia nigra pars compacta.
We have collected DNA samples from 65 members of this family, including from 13 affected individuals (Supplementary Fig. 1 ). We performed genome-wide linkage analysis using over 300 microsatellite polymorphic markers and, subsequently, a dense panel of 21 microsatellite markers on chromosome 20p. A two-point logarithm of odds (LOD) score over 3.3 and a multipoint LOD score over 3.8 were obtained for several informative markers on the tip of chromosome 20 (Supplementary Table 1 ). We constructed a genetic haplotype that was shared by all 13 affected family members but not by the 2 older unaffected individuals (II-9 and II-12) in the second generation ( Supplementary Figs. 1 and 2) . Individual II-9 died at age 87 years without any signs of Parkinson's disease. Individual II-12 died at age 78 years without symptoms of Parkinson's disease, and there was no Parkinson's disease pathology at autopsy. Neither of these unaffected family members in the second generation carried the disease-linked haplotype. A crossover between the D20S901 and D20S894 markers observed in affected individuals II-1 and III-1 defined the lower border of the shared haplotype ( Supplementary Fig. 1 ), thus establishing a locus for the autosomal dominant, clinically typical and Lewy body-confirmed Parkinson's disease in this family in a minimum candidate region (MCR) of 10.7 Mb at 20pter-p12, telomeric to the D20S894 marker on the short arm of chromosome 20.
Mutations in TMEM230 in Parkinson's disease
There are a total of 141 known genes in the 20pter-p12 MCR. We initially analyzed the exons of 17 protein-coding genes in one affected individual (II-11) by Sanger sequencing, but we did not find any new variants (Supplementary Table 2 ). We then employed a whole-exome sequencing approach. We selected one unaffected individual (II-9), who lived to 87 years old without Parkinson's disease, and four distantly related affected individuals (II-4, III-1, III-20 and III-26), so that the number of cosegregating variants not linked to Parkinson's disease could be reduced.
Across these five individuals, we identified a total of 90,289 variants. We excluded variants with an average heterozygosity of >0.01 in multiple databases, including the dbSNP (v130), HapMap and 1000 Genome Project databases. After filtering for variants with functional consequences (nonsense, missense and splice-site variants) and removing tolerated variants, a single missense variant (c.422G>T; p.Arg141Leu) (NM_001009923) in TMEM230 was left. This variant was present in the four patients with Parkinson's disease but not in the unaffected individual. We performed Sanger sequencing and cosegregation analysis using all additional samples available to us from this family (Supplementary Table 3 ). The mutation encoding p.Arg141Leu fully cosegregated with disease in this large kindred ( Supplementary Figs. 1 and 3a) . All 13 affected individuals whose DNA samples were available for sequencing analysis carried this mutation. This mutation was also presumably present in the other two affected deceased individuals (I-1 and II-8), as evidenced by transmission of the mutation to their offspring. This mutation was not present in any SNP databases with a total of 15,184 sequenced alleles (Supplementary Table 4) . We further sequenced a control cohort of 1,238 samples from North America, and we did not find this mutation (Supplementary Table 4) . Consistent with our linkage data, TMEM230 is located at 20p13, about 5.1 Mb from 20pter, in the middle of our mapped 10.7-Mb MCR.
In addition to the TMEM230 mutation encoding p.Arg141Leu, two other variants were identified on the affected chromosome in our unfiltered exome sequencing data. These two variants were also located in the MCR but were present in intronic regions, without apparent functional consequences (Supplementary Table 5 ). To ensure that all the exons in the MCR were fully and sufficiently covered, we further performed Sanger sequencing of all ten exons that had relatively lower coverage of ≤20× (2-20×) in our exome sequencing data. We did not find any new variants in the MCR on the affected chromosome. Thus, the TMEM230 mutation encoding p.Arg141Leu seemed to be the only missense variant shared in the MCR by all the patients in this large family with Parkinson's disease.
To examine whether TMEM230 mutations are present in other patients with Parkinson's disease, we analyzed 832 DNA samples collected from North America, including 433 familial and 399 sporadic Parkinson's disease cases. We found two mutations in TMEM230. A c.551A>G mutation was identified in a patient with familial Parkinson's disease. This mutation changes the stop codon to a tryptophan residue and adds six amino acids (WHPPHS) at the C terminus of the encoded protein (p.*184Trpext*5) (Supplementary Fig. 3b ). The male patient harboring this mutation had disease onset at the age of 33 years. His maternal male cousin was described to have Parkinson's disease, with disease onset at the age of 35 years. No additional information or DNA samples from this family were available for further analysis. The other mutation, c.275A>G (p.Tyr92Cys), was identified in a male patient with sporadic Parkinson's disease having disease onset at age 34 years (Supplementary Fig. 3c ). His mother carries this mutation and had no signs of Parkinson's disease when evaluated at 57 years old. Similarly, the mutations encoding p.*184Trpext*5 and p.Tyr92Cys were not present in SNP databases with a total of 15,184 alleles sequenced or in over 1,000 in-house controls (Supplementary Table 4 ). The p.*184Trpext*5 and p.Tyr92Cys alterations were identified in a single patient each, and their pathogenicity in Parkinson's disease remains to be further examined. Through our screening, we also found three other missense variants, which are known SNPs, at similar frequencies in the Parkinson's disease and control cohorts (Supplementary Table 4) , and these SNPs did not cosegregate with Parkinson's disease in respective families ( Supplementary Fig. 4) .
To test whether mutations in TMEM230 cause Parkinson's disease in other patients with different ancestry, we extended our genetic study to a Chinese cohort with 574 Parkinson's disease cases, including 225 familial index cases and 349 sporadic cases. We identified a single mutation, c.550_552delTAGinsCCCGGG, in seven familial index cases from seven unrelated families but not in the sporadic cases ( Supplementary Figs. 3d and 5-11) . In this mutation, the TAG stop codon is replaced by six nucleotides, CCCGGG, resulting in replacement of the stop codon with proline and glycine and the addition of seven amino acids (PGHPPHS) at the C terminus of the encoded protein (p.*184ProGlyext*5) (Supplementary Fig. 3d) . Notably, the last five amino acids (HPPHS) are identical in the *184Trpext*5 and *184ProGlyext*5 mutants (Fig. 1a) . In two families with additional DNA samples available from other patients with Parkinson's disease, we could confirm the cosegregation of disease with the mutation encoding p.*184ProGlyext*5 ( Supplementary Figs. 8 and 11) . Of the nine patients with Parkinson's disease from seven families harboring the mutation encoding p.*184ProGlyext*5, five patients from four families were homozygotes for the mutation (Supplementary Figs. 1d, 
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A r t i c l e s 5, 6, 9 and 11). To test whether mutations in other known Parkinson's disease-linked genes, such as SNCA, LRRK2 and VPS35, or other parkinsonism-linked genes were present in these Chinese patients with Parkinson's disease, we further performed whole-exome sequencing using DNA samples from the nine Chinese patients with Parkinson's disease harboring the p.*184ProGlyext*5 alteration. We did not find new variants in these genes. We performed Sanger sequencing of DNA samples from our 528 in-house Chinese controls, and we did not find the mutation encoding p.*184ProGlyext*5. Moreover, this mutation was not present in the Chinese exome sequencing database, which included 9,906 neurologically normal Chinese controls, from BGIShenzhen. Notably, none of the four TMEM230 mutations identified in patients with Parkinson's disease in this study, including those encoding p.Arg141Leu, p.Tyr92Cys, p.*184Trpext*5 and p.*184ProGlyext*5, was present in the Exome Aggregation Consortium (ExAC) database in a total of 60,706 unrelated individuals.
The apparent aggregation of homozygotes for the mutation encoding p.*184ProGlyext*5 in the Chinese familial Parkinson's disease cohort may suggest increased penetrance of this mutation in the homozygous state in late-onset Parkinson's disease due to a dose effect. The obligate heterozygous mother of a homozygous patient had not developed Parkinson's disease before she died at 96 years old ( Supplementary Fig. 6 ), which may suggest incomplete penetrance of this mutation in the heterozygous state in some mutation carriers.
To test whether the high prevalence of the mutation encoding p.*184ProGlyext*5 in the Chinese patients with Parkinson's disease is due to a founder effect, we analyzed three intragenic SNPs in TMEM230 closely flanking the mutation site in five patients homozygous for the mutation (Supplementary Fig. 12 ). The presence of heterogeneity for these SNPs in four of the five patients homozygous for the mutation encoding p.*184ProGlyext*5 suggests that the mutation either arose independently or is very ancient (Supplementary Fig. 12 ). The p.*184Trpext*5 and p.*184ProGlyext*5 alterations were identified in different populations, but both affect the stop codon, suggesting that this codon is a hotspot for Parkinson's disease-linked variants. The mutation encoding p.*184ProGlyext*5 accounted for 7 of 225 (3.1%) of Chinese index cases with familial Parkinson's disease in our cohort, seeming to be the most prevalent single genetic defect in Chinese familial Parkinson's disease. Notably, Arg141, Tyr92 and the stop codon (codon 184) are highly evolutionally conserved (Fig. 1a) .
TMEM230 in synaptic vesicles in neurons
TMEM230, also known as C20orf30, is a gene yet to be experimentally characterized. There is no apparent sequence homology to any other known genes or proteins. There are four major alternatively spliced mRNA variants synthesized from five exons in humans ( Supplementary Fig. 13a ). mRNA variant 1 encodes protein isoform 1, a polypeptide of 183 amino acids. The three other mRNA variants (variants 2-4) encode protein isoform 2, a polypeptide of 120 amino acids (Supplementary Fig. 13a ). In humans, isoform 2 lacks the N-terminal 63 amino acids of isoform 1. Across species spanning zebrafish to most mammals, there is only a single protein isoform of 120 amino acids that is equivalent to human isoform 2. The longer isoform 1 appears to be present only in primates. The N-terminal polypeptides for isoform 1 in primates are divergent in size and homology. However, the C-terminal polypeptides with 120 amino acids, which are identical to isoform 2 in humans, are highly conserved, suggesting functional importance for isoform 2.
We characterized the transcriptional and translational profiles of human TMEM230. Our data suggest that isoform 2 accounts for >95% of the total protein isoforms (Supplementary Fig. 13 ).
TMEM230 encodes a putative transmembrane protein (TMEM230) of unknown localization and function. Computational predictions of protein structure and function suggested that this protein has two major α-helical domains (Fig. 1b) and two transmembrane segments, with the N-terminal and C-terminal regions exposed to the cytosol [25] [26] [27] (Fig. 1c) . Notably, all four Parkinson's disease-associated mutations mapped to the loop regions (Fig. 1c) . p.Tyr92Cys, p.*184Trpext*5 and p.*184ProGlyext*5 were not predicted to remarkably alter protein structure. However, the positively charged Arg141 residue in wildtype TMEM230 was predicted to be located on the luminal site of the membrane, adjacent to the second transmembrane segment. When Arg141 was mutated to Leu141, Leu141 appeared to be a part of the second transmembrane segment and was buried in the membrane.
To examine the subcellular localization of TMEM230 protein, we performed immunohistochemical staining of mouse brain sections. Mouse Tmem230 appeared to localize to vesicle structures in neurons, including dopaminergic neurons in the substantia nigra (Supplementary Fig. 14) . To characterize these structures, we engineered 25 human TMEM230 constructs in three expression vectors and performed confocal microscopy using transiently transfected human SH-SY5Y and mouse Neuro-2a cells. Human TMEM230 showed a similar pattern of membrane-bound distribution in both these cell types, but Neuro-2a cells showed better morphological detail owing to their relatively larger size (Supplementary Fig. 15 ). Therefore, we used Neuro-2a cells for further characterization. 
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We observed that the vesicle structures labeled by TMEM230 were predominantly located in the perinuclear region as clusters and in other cytosolic areas as isolated vesicles or vesicle clusters ( Supplementary  Fig. 15a-o) . Isoforms 1 and 2 showed similar patterns of distribution ( Supplementary Fig. 15a-o) . An eGFP or DsRed tag at the C terminus of the protein did not affect its subcellular distribution ( Supplementary Fig. 15a-o) .
To characterize the vesicle structures labeled by TMEM230, we tested several subcellular organelle markers. TMEM230 did not colocalize with markers for mitochondria, lysosomes or endoplasmic reticulum (Supplementary Fig. 16a-l) . The perinuclear clusters labeled by TMEM230 were in close proximity to the Golgi apparatus but were distinct from signal for GOLGA2, a cis-Golgi matrix protein (Supplementary Fig. 16m-p) . We then examined syntaxin 6 (STX6), a transmembrane protein predominantly enriched in the trans-Golgi network (TGN). We found that STX6 colocalized with TMEM230 in perinuclear clusters and in some vesicles (Supplementary Fig. 16q-t) , suggesting that the perinuclear structures labeled by TMEM230 correspond to the TGN and possibly to secretory budding and recycling (secretory/recycling) vesicles.
To test whether the TMEM230-labeled secretory vesicles evolve into synaptic vesicles, which are the most abundant secretory/recycling vesicles in neurons, we examined synaptophysin (SYP), vesicle-associated membrane protein 2 (VAMP2) and vesicular monoamine transporter 2 (VMAT2), three known transmembrane proteins of synaptic vesicles. We observed colocalization of TMEM230 and these synaptic vesicle markers (Supplementary Fig. 17a-l and data not shown) . The Parkinson's disease-linked mutations did not alter the localization pattern of the protein (Supplementary Fig. 17i-l and data not shown) . We confirmed the colocalization of human TMEM230 with endogenous mouse Syp and Vmat2 in mouse embryonic primary neurons, including dopaminergic neurons (Fig. 2a-h ). Endogenous mouse Tmem230 was also shown to colocalize to vesicles with endogenous Syp and Vmat2 in non-transfected mouse primary neurons (Fig. 2i-p) . Immunoblot data from rat brain synaptosome fractionation showed that Tmem230 had an enrichment pattern similar to that of Syp (Fig. 2q) , and immunogold electron microscopy indicated that Tmem230 is located in the synaptic vesicle pool region in the presynapse (Fig. 2r) . These data, therefore, indicate that TMEM230 is primarily a transmembrane protein of synaptic vesicles in neurons.
TMEM230 in recycling endosomes
Synaptic vesicles are continuously recycled through endocytic mechanisms after exocytosis to replenish the reserve vesicle pool 28 . RAB GTPases and other signaling proteins coordinate the sorting, trafficking and recycling of these vesicles. Most early endocytic steps rely on RAB5A, which mediates fusion of endocytic vesicles to form early endosomes 29 . To test whether TMEM230 is present in early endosomes, we cotransfected mouse Neuro-2a cells with human TMEM230 and RAB5A constructs and found that TMEM230 and RAB5A colocalized in early endosomes (Supplementary Fig. 18a-d) .
Early endosomes have three distinct destinations, depending on the sorting signals present on the endosomes: degradation in the lysosomes, recycling to the plasma membrane or retrieval to the Golgi apparatus. We examined several proteins in these pathways and found that TMEM230 seemed to partially and weakly colocalize with RAB7 ( Supplementary Fig. 18e-h) , a protein that contributes to the biogenesis of late endosomes and autophagosomes and subsequent trafficking to lysosomes. Similarly, TMEM230 signal also partially and weakly colocalized with MAP1LC3A ( Supplementary  Fig. 18i-l) , an autophagosome marker. We observed that the majority of RAB11A-labeled vesicles were consistently positive for TMEM230 (Supplementary Fig. 18m-p) , suggesting that a major fraction of TMEM230-labeled synaptic vesicles is to evolve into recycling endosomes, leading to the direct reuse of the synaptic vesicles, as expected.
Endosome retrieval to the TGN is mediated by the retromer complex. A p.Asp620Asn substitution in VPS35, a component of the retromer complex, has previously been reported in several families with autosomal dominant Parkinson's disease 10, 11 . To test whether TMEM230 is involved A r t i c l e s in vesicle retrieval to the TGN by the retromer complex, we transfected Neuro-2a cells with both TMEM230 and VPS35 constructs, and we observed that a remarkable fraction of the TMEM230 signal overlapped with the VPS35 signal ( Fig. 3a-d) . We confirmed this finding using primary mouse neurons (Fig. 3e-p Fig. 19 ). 
Impairment of synaptic vesicle trafficking by TMEM230 mutations
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A r t i c l e s of synaptic vesicles, as shown by reduced transport speed, track length and displacement length, in comparison to cells expressing wild-type protein (Fig. 4) . Increased expression of SNCA by duplication and triplication has been shown to cause Parkinson's disease [34] [35] [36] . Our observations of colocalization of SNCA and TMEM230 in some vesicles and vesicle clusters in Parkinson's disease autopsy samples, together with impairment of vesicle trafficking by expression of TMEM230 mutant proteins, raise the possibility that TMEM230 mutations might lead to impaired SNCA degradation and, therefore, increased SNCA levels in cells. We explored this possibility in HEK293 cells and observed mild-to-moderate but consistent increases in SNCA levels in cells expressing the mutant proteins when compared to those expressing wild-type protein (Supplementary Fig. 20) .
DISCUSSION
Here we report a fully cosegregating mutation in TMEM230 in a large family with autosomal dominant, clinically typical and Lewy bodyconfirmed Parkinson's disease. A variant in DNAJC13 (p.Asn855Ser) was recently reported in this family 37 , which did not fully cosegregate with disease, as demonstrated by the absence of this variant in three affected individuals (II-1, III-1 and III-23) 37 . Moreover, this variant was present in the unaffected individual (II-9) who had not developed any signs of Parkinson's disease when she died at the age of 87 years. The inconsistency of genotype-phenotype correlations in multiple individuals raised the concern that the p.Asn855Ser variant in DNAJC13 might not be the disease-causing variant in this family, as the authors also noted 37 . We performed linkage analysis and established a Parkinson's disease locus at 20pter-p12 using this family. Our whole-exome sequencing complemented by Sanger sequencing covered all known transcripts in the MCR and identified a c.422G>T mutation (encoding p.Arg141Leu) in TMEM230 as the only missense mutation that fully cosegregates with disease in the entire family. Moreover, we also found a highly prevalent TMEM230 mutation, encoding p.*184ProGlyext*5, in nine patients with Parkinson's disease from seven Chinese families. Together, these data provide compelling genetic evidence that TMEM230 is the Parkinson's disease-causing gene on the chromosome 20p locus in these families. These data also indicate that, although a disease-modifying effect for DNAJC13 p.Asn855Ser could not be excluded 37 , this variant is not the disease-causing variant in this large family with Parkinson's disease.
Among autopsy samples from four deceased patients (II-1, II-4, II-6 and II-14) in the second generation of the large family, three had confirmed Lewy body pathology. Patient II-1 had all the cardinal symptoms of Parkinson's disease, with a moderate response to levodopa. In addition, this patient had other clinical signs, including pseudobulbar affect, dysphagia and dementia. Pathological analysis of autopsy samples from this patient showed progressive supranuclear palsy (PSP) pathology. However, the son of this patient (III-1) developed typical Parkinson's disease symptoms at the age of 49 years, with good response to levodopa. It remains to be further investigated why the same TMEM230 mutation encoding p.Arg141Leu leads to PSP in one case but to Parkinson's disease in other cases in this family. This phenotypic heterogeneity may not be an exception, as some patients with a p.Arg1441Cys or p.Arg1441His substitution in LRRK2, two well-established Parkinson's disease-causing variants, have also been shown to present with clinical and pathological features of PSP 7, 38, 39 . These data may suggest an etiological link between Parkinson's disease and PSP.
Parkinson's disease and other parkinsonian disorders are typically sporadic, but disease-causing mutations in several genes have been identified in monogenically inherited forms. Of these genes, TMEM230 seems to be the only gene that encodes a transmembrane protein of synaptic vesicles. Synaptic vesicles are the most abundant secretory/recycling vesicles in neurons. The precise functions of the TMEM230 protein and pathogenic mechanism in Parkinson's disease mediated by TMEM230 mutation remain to be further elucidated. On the basis of its molecular features and relationship with the synaptic vesicle and endosomal markers tested in this study, we propose that TMEM230 is a trafficking protein of secretory/recycling vesicles, primarily involved in exocytosis, endocytosis and recycling of synaptic vesicles in neurons, and that dysfunction of synaptic vesicles, such as impaired trafficking and recycling, underlies the pathogenesis of Parkinson's disease linked to TMEM230 mutation.
On the basis of the criteria proposed by Langston et al. 1 , TMEM230 seems to be the third disease-causing gene linked to clinically typical and Lewy body-confirmed Parkinson's disease, after SNCA and LRRK2 (ref. 1). VPS35 mutations have been linked to autosomal dominant dopa-responsive parkinsonism. However, limited brain tissue analysis failed to show Lewy body pathology and thus did not allow definitive conclusions for Lewy body disease 10, 40 . Our data suggest that TMEM230 and VSP35 may share a functional pathway in synaptic vesicle and endosome retrograde trafficking. Interestingly, LRRK2 may also be involved in vesicle trafficking processes. A recent study has shown that LRRK2 phosphorylates a subset of RAB proteins, which have important roles in intracellular vesicle trafficking, and Parkinson's disease-linked LRRK2 mutations increase the phosphorylation of these RAB proteins and inhibit their activity, which may disturb intracellular vesicle trafficking 41 . Thus, the defects in synaptic vesicle and endosome trafficking may correspond to a convergent pathway in the pathogenesis of Parkinson's disease. Our findings also suggest that modulation of synaptic vesicle and endosome trafficking in the brain may have therapeutic effect. Indeed, NAB2, a small molecule that promotes endosomal trafficking, has recently been shown to be able to reverse Parkinson's disease-related pathological phenotypes in neurons derived from patients with Parkinson's disease harboring a mutation encoding p.Ala53Thr in SNCA 42, 43 .
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Patients and samples. This study has been approved by the Northwestern University Institutional Review Board (study 12722). Clinical data were collected by neurologists and by examination of medical records. DNA and other samples were taken after obtaining written informed consent. DNA samples from 65 family members of large Parkinson's disease pedigree 9853 were used for linkage analysis and for identification of the initial mutation in TMEM230. In addition, DNA samples from 832 index cases (433 with familial Parkinson's disease and 399 with apparently sporadic Parkinson's disease) were used to screen for TMEM230 mutations, including 369 samples from the Coriell Institute and 463 in-house samples collected in North America. Another Parkinson's disease cohort, including 574 Chinese Parkinson's disease cases (225 familial and 349 sporadic), was screened for TMEM230 mutations. In total, 1,406 (658 familial and 748 sporadic) Parkinson's disease cases were screened for mutations in these two cohorts from different populations. Mutations in TMEM230 were also screened for in over 1,000 North American controls and over 500 Chinese controls. Primer sequences for PCR amplification and Sanger sequencing are included in Supplementary Table 3 . Midbrain and neocortex sections from the autopsy samples of ten cases with Parkinson's disease and seven cases with DLB were used for confocal microscopy.
Other linkage information for Parkinson's disease pedigree 9853. On the basis of the transmission pattern of the disease in three generations of this kindred, sex chromosome-linked (X-linked and Y-linked) transmission was excluded, and autosomal dominant inheritance was established. Mutations in the Parkinson's disease-linked genes known at that time (SNCA, PARK2, PINK1 and PARK7) were excluded by direct Sanger sequencing analysis. We then performed genome-wide linkage analysis using over 300 microsatellite polymorphic markers in previously described protocols 44 . The major known Parkinson's disease loci were excluded through detailed analysis. Instead, positive LOD scores were obtained with microsatellite markers on the short arm of chromosome 20. We further analyzed this region using a dense panel of 21 microsatellite markers.
Whole-exome sequencing. The basic protocols for sequence capture, nextgeneration sequencing, alignment and base calling and for in silico analysis have been described elsewhere 45 Base calling was performed with the Illumina CASAVA 1.6 pipeline, and reads were aligned to the hg19 reference genome using Genome Analysis Toolkit (GATK) v1.1. The UnifiedGenotyper from GATK calls both variants and indels and performs VQS (variant quality score) recalibration and genotype refinement to make accurate variant calls. Additionally, the UnifiedGenotyper generates normalized Phred-scaled likelihood scores without priors for each alternate genotype. Variants with VQSLOD <−3 and alternate Phred-scaled likelihood scores <99 were excluded from the remainder of the analysis. All remaining variants were annotated using ANNOVAR. Variants were screened against multiple databases, including the dbSNP (v130), HapMap and 1000 Genomes Project databases. Variants with minor allele heterozygosity of >0.01 were excluded from further analysis. The GERP (Genomic Evolutionary Rate Profiling) and phastCons (Phylogenetic Analysis with Space/Time Models) conservation scores were both obtained through ANNOVAR. PolyPhen-2 was used to predict the effects of amino acid changes on protein functional status. The SpliceView, NNsplice and ESEfinder programs were used to predict the effect of variants on splicing. The average read coverage per targeted base was >65× with a Phred quality score of ≥30 in all samples.
RT-PCR and clonal analysis of TMEM230 transcriptional variants in the brain. Two primers were synthesized (TMEM230-RT1, 5′-CAGAAGCTTGAG TGGCACTTAAGCGGGCCATGC-3′; TMEM230-RT2, 5′-CAGCTCGAGGG ACAGTTCCACTGTGACTCCT-3′) for PCR amplification of the FirstChoice PCR-Ready Human Brain cDNA library (AM3324, Ambion). The PCR products were digested with HindIII and XhoI, purified by agarose gel and cloned into the pBluescript M13(−) plasmid. Individual pBluescript M13(-) plasmid clones were sequenced using TMEM230-RT1 as the primer. The sequences were aligned with genomic DNA to identify mRNA transcriptional variants.
